Reacta Healthcare Transforms Facility for Multi-Allergen Manufacturing to Address Food Allergies

Reacta Healthcare's Groundbreaking Transformation

In May 2025, Reacta Healthcare reached a significant milestone with the initiation of the first production run of pharmaceutical-grade milk and egg challenge meals. This innovation marks a pivotal step toward enhancing the diagnosis and treatment of food allergies, an issue affecting millions worldwide.

With 46% of adults and 40% of children suffering from multiple food allergies, healthcare providers are increasingly recognizing the necessity of a holistic approach in their diagnosis and treatment methods. The introduction of egg and milk challenge meals complements Reacta Healthcare's existing peanut products, highlighting the company's commitment to addressing the realities of food allergy prevalence.

These new challenge meal products are not only meticulously designed to fulfill the specific needs of clinical and research communities but they also adhere to stringent safety, quality, and efficacy standards across various allergens. The ability to expand Reacta's product portfolio effortlessly to include further allergens positions the company favorably in the ever-evolving landscape of food allergy research.

The entire development and manufacturing process of these challenge meals has occurred at Reacta Healthcare's Medicines and Healthcare products Regulatory Agency (MHRA) licensed facility in Deeside, UK. The challenge meals have been crafted in accordance with client stipulations regarding allergen identification, standardization, and cGMP (current Good Manufacturing Practice) manufacturing compliance, ensuring that each product meets rigorous health agency requirements, including submissions to the FDA and EMA.

Reacta's challenge meals are particularly suitable for deployment during all phases of clinical trials, serving a critical role in double-blind placebo-controlled oral food challenges, a key practice in allergy diagnosis and monitoring. Now with the addition of two more allergens, Reacta is optimally positioned to deliver a multitude of challenge meal combinations tailored to the growing clinical research community that seeks an 'antigen-agnostic' indication for their therapeutic endeavors.

The multi-allergen facility is meticulously set up to facilitate seamless development of an expanded range of allergen challenge meals. With prototypes already developed for hazelnut and cashew, Reacta is leveraging its internal research and development capabilities to push the boundaries of food allergy therapy, diagnosis, and clinical practices.

ABOUT REACTA HEALTHCARE

Established as a leader in the healthcare sector, Reacta Healthcare operates from a UK-based MHRA licensed pharmaceutical manufacturing facility. Their globally patented challenge meals are utilized in therapeutic trials across the globe for diagnosing and monitoring food allergies, showcasing the company's dedication to innovating solutions in this vital area of health.

As Reacta Healthcare continues to expand its offerings, it remains poised to play a crucial role in food allergy research, helping to foster enhanced understanding and treatment for individuals affected by these conditions.